Four years of durable OLE data and Phase 3 enrollment complete — zorevunersen's NDA case hinges on whether Phase 3 confirms the signal

Bull

A positive outcome would be statistically significant reduction in convulsive seizure frequency at the 28-week primary endpoint versus sham control, ideally accompanied by improvements in cognition or behavioral endpoints consistent with the four-year OLE data. This would substantiate the durable OLE signal in a controlled setting, provide the pivotal evidence needed to complete the rolling NDA submission, and position zorevunersen as a disease-modifying therapy rather than a symptomatic add-on — a meaningful differentiation in Dravet syndrome.

Bear

The most likely failure modes are a primary endpoint miss on convulsive seizure frequency reduction that does not achieve statistical significance, potentially due to higher-than-expected placebo/sham response rates in a pediatric epilepsy trial, or heterogeneity in SCN1A variant populations diluting the treatment effect. A technically positive but clinically modest effect size — insufficient to demonstrate meaningful differentiation from existing approved adjunctive therapies — would also constitute a materially negative outcome, undermining the NDA package and the disease-modification narrative built on OLE data.